These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
504 related articles for article (PubMed ID: 18071939)
1. Historical development of monoclonal antibody therapeutics. Nissim A; Chernajovsky Y Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939 [TBL] [Abstract][Full Text] [Related]
2. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes]. Siberil S; Dutertre CA; Boix C; Teillaud JL Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389 [TBL] [Abstract][Full Text] [Related]
3. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal and recombinant antibodies, 30 years after .. Laffly E; Sodoyer R Hum Antibodies; 2005; 14(1-2):33-55. PubMed ID: 16424599 [TBL] [Abstract][Full Text] [Related]
5. [Monoclonals antibodies: a recent and major therapeutic advance]. Paintaud G; Lejarre F; Ternant D; Goupille P; Watier H Therapie; 2009; 64(1):1-7. PubMed ID: 19463247 [TBL] [Abstract][Full Text] [Related]
6. Three decades of human monoclonal antibodies: past, present and future developments. Steinitz M Hum Antibodies; 2009; 18(1-2):1-10. PubMed ID: 19478393 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic antibodies--delivering the promise? Hale G Adv Drug Deliv Rev; 2006 Aug; 58(5-6):633-9. PubMed ID: 16822575 [TBL] [Abstract][Full Text] [Related]
8. Engineered antibodies take center stage. Huston JS; George AJ Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424 [TBL] [Abstract][Full Text] [Related]
9. Development of humanized antibodies as cancer therapeutics. Qu Z; Griffiths GL; Wegener WA; Chang CH; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM Methods; 2005 May; 36(1):84-95. PubMed ID: 15848077 [TBL] [Abstract][Full Text] [Related]
10. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. Mascelli MA; Zhou H; Sweet R; Getsy J; Davis HM; Graham M; Abernethy D J Clin Pharmacol; 2007 May; 47(5):553-65. PubMed ID: 17379759 [TBL] [Abstract][Full Text] [Related]
11. Preparation of genetically engineered monoclonal antibodies for human immunotherapy. Parren PW Hum Antibodies Hybridomas; 1992 Jul; 3(3):137-45. PubMed ID: 1391663 [TBL] [Abstract][Full Text] [Related]
12. [Antibody Engineering: From the Idea to Its Implementation]. Polanovsky OL Mol Biol (Mosk); 2017; 51(6):1039-1045. PubMed ID: 29271966 [TBL] [Abstract][Full Text] [Related]
13. [The expression technology of chimeric and humanized antibodies]. Ishida T; Imai K Nihon Rinsho; 2002 Mar; 60(3):439-44. PubMed ID: 11904955 [TBL] [Abstract][Full Text] [Related]
14. Establishment of hapten-specific monoclonal avian IgY by conversion of antibody fragments obtained from combinatorial libraries. Deckers S; Braren I; Greunke K; Meyer N; Rühl D; Bredehorst R; Spillner E Biotechnol Appl Biochem; 2009 Jan; 52(Pt 1):79-87. PubMed ID: 18627355 [TBL] [Abstract][Full Text] [Related]